Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
GNPX 
Genprex Inc (GNPX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/24/2025: GNPX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.5
1 Year Target Price $7.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.55% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.76M USD | Price to earnings Ratio 0.1 | 1Y Target Price 7.5 |
Price to earnings Ratio 0.1 | 1Y Target Price 7.5 | ||
Volume (30-day avg) 1 | Beta -0.8 | 52 Weeks Range 1.75 - 55.00 | Updated Date 11/22/2025 |
52 Weeks Range 1.75 - 55.00 | Updated Date 11/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 42.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -207.41% | Return on Equity (TTM) -612.3% |
Valuation
Trailing PE 0.1 | Forward PE - | Enterprise Value 3119528 | Price to Sales(TTM) - |
Enterprise Value 3119528 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.18 | Shares Outstanding 1631841 | Shares Floating 668212 |
Shares Outstanding 1631841 | Shares Floating 668212 | ||
Percent Insiders 1.18 | Percent Institutions 1.56 |
Upturn AI SWOT
Genprex Inc
Company Overview
History and Background
Genprex Inc. was founded in 2009. It is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer. The company's key technology platform is based on gene therapy, aiming to deliver therapeutic genes to cancer cells to induce an anti-tumor immune response. Significant milestones include the progression of its lead drug candidate, REQORSAu00ae, through clinical trials.
Core Business Areas
- Oncology Therapeutics: Genprex is primarily engaged in the research, development, and commercialization of gene-based immunotherapies for cancer. Its core focus is on developing treatments that activate the patient's immune system to fight cancer.
Leadership and Structure
Genprex Inc. is led by a management team with experience in biotechnology and pharmaceuticals. The organizational structure is typical for a clinical-stage biopharmaceutical company, with departments focused on research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- Product Name 1: REQORSAu00ae (quaratusugene ozaur GPC-101): A novel gene therapy that delivers the tumor suppressor gene, p53, to cancer cells. It is designed to work in conjunction with standard chemotherapy to enhance the body's immune response against cancer. Competitors include pharmaceutical companies developing various immunotherapy agents and targeted therapies for lung cancer and other solid tumors. Specific market share data for REQORSA is not publicly available as it is still in clinical development.
Market Dynamics
Industry Overview
The oncology market is a rapidly growing and highly competitive sector within the biopharmaceutical industry. There is a significant focus on developing innovative therapies, including immunotherapies, targeted therapies, and gene therapies, to address unmet medical needs in cancer treatment.
Positioning
Genprex is positioned as a clinical-stage biopharmaceutical company developing a novel gene therapy for cancer. Its competitive advantage lies in its unique approach of delivering the p53 tumor suppressor gene to induce an immune response, potentially offering a new treatment modality for various cancers.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is vast and continues to expand with advancements in research and a growing global cancer incidence. Genprex's TAM is specifically focused on the market segments addressable by its lead product, REQORSAu00ae, particularly in non-small cell lung cancer (NSCLC) and other solid tumors. The company is positioned to capture a portion of this market with a successful development and commercialization of its therapies.
Upturn SWOT Analysis
Strengths
- Novel gene therapy platform with potential to address significant unmet medical needs in cancer.
- Experienced management team with expertise in biotechnology and drug development.
- Focus on a well-validated tumor suppressor gene (p53).
- Potential for combination therapies to enhance efficacy.
Weaknesses
- Clinical-stage company with no approved products, leading to significant financial risk.
- Reliance on a single lead product candidate (REQORSAu00ae).
- Challenges inherent in gene therapy development and manufacturing.
- Limited historical financial performance and revenue generation.
Opportunities
- Expanding market for cancer immunotherapies.
- Potential for accelerated regulatory pathways for promising oncology drugs.
- Strategic partnerships and collaborations to advance clinical trials and commercialization.
- Exploration of REQORSAu00ae in other cancer types.
Threats
- Clinical trial failures or unexpected adverse events.
- Competition from established pharmaceutical companies and emerging biotechs.
- Regulatory hurdles and delays in drug approval.
- Funding challenges for a clinical-stage company.
- Reimbursement challenges for novel therapies.
Competitors and Market Share
Key Competitors
- Bristol Myers Squibb (BMY)
- Merck & Co. (MRK)
- Roche Holding AG (RHHBY)
- Pfizer Inc. (PFE)
- Eli Lilly and Company (LLY)
- Moderna, Inc. (MRNA)
Competitive Landscape
Genprex faces intense competition from large pharmaceutical companies with established oncology portfolios and significant R&D budgets. Its advantage lies in its specialized gene therapy approach, which, if successful, could offer a unique treatment option. However, it faces disadvantages in terms of scale, established sales and marketing infrastructure, and financial resources compared to its larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historically, Genprex's growth has been characterized by its progression through preclinical and early-stage clinical development. This growth is measured by advancements in its pipeline and expansion of its intellectual property portfolio.
Future Projections: Future growth projections are highly dependent on the successful outcome of clinical trials for REQORSAu00ae and subsequent regulatory approvals. Analyst estimates, if available, would focus on potential peak sales upon market entry and the expansion of its product pipeline.
Recent Initiatives: Recent initiatives likely involve the advancement of clinical trials for REQORSAu00ae, potentially exploring new indications, and seeking strategic partnerships or funding to support ongoing development.
Summary
Genprex Inc. is a clinical-stage biopharmaceutical company with a novel gene therapy for cancer, REQORSAu00ae. Its strength lies in its innovative technology targeting the p53 gene. However, it faces significant weaknesses due to its early stage, reliance on one key product, and high financial risk. Opportunities exist in the growing immunotherapy market, but threats from clinical trial failures, competition, and funding challenges are substantial. The company needs to successfully navigate clinical trials and secure further funding to realize its potential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC filings (e.g., 10-K, 10-Q)
- Financial news and analysis platforms
- Industry reports
- Company press releases
Disclaimers:
This JSON output is a structured overview based on publicly available information and general industry knowledge. It is not intended as financial advice. Investing in clinical-stage biotechnology companies carries significant risk. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data for early-stage companies is often estimated or unavailable.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genprex Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2018-03-29 | President, CEO, CFO & Director Mr. Ryan M. Confer M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.genprex.com |
Full time employees 13 | Website https://www.genprex.com | ||
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.